Ignite Creation Date:
2024-05-06 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 1:55 PM
Study NCT ID:
NCT04733105
Status:
COMPLETED
Last Update Posted:
2021-11-09
First Post:
2021-01-24
Brief Title:
Pronostic Value of Type I ANTi-Interferon Antibodies in Patients With COVID-19 Acute Respiratory Failure
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Assistance Publique - Hôpitaux de Paris
Study Overview
Official Title:
Pronostic Value of Type I ANTi-Interferon Antibodies in Patients With COVID-19 Acute Respiratory Failure a Multicenter Observational Study
Status:
COMPLETED
Status Verified Date:
2021-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ANTICOV
Brief Summary:
Severe SARS-CoV-2 infections are frequently associated with the acute respiratory distress syndrome ARDS which leads to a mortality of 30-40 An altered type I interferon IFN response has been demonstrated in patients with severe COVID-19 together with a high viral load
The aim of the current work is in a large cohort of patients with severe COVID-19 admitted in the ICU to determine the prevalence of patients with positive anti-IFN antibodies and to determine their outcome as compared to patients having negative anti-IFN antibodies
The aim of the current work is in a large cohort of patients with severe COVID-19 admitted in the ICU to determine the prevalence of patients with positive anti-IFN antibodies and to determine their outcome as compared to patients having negative anti-IFN antibodies
Detailed Description:
Severe SARS-CoV-2 infections are frequently associated with the acute respiratory distress syndrome ARDS which leads to a mortality of 30-40 An altered type I interferon IFN response has been demonstrated in patients with severe COVID-19 together with a high viral load A recent study revealed that 10 of patients admitted in the intensive care unit ICU for severe COVID-19 had positive type I anti-IFN antibodies Such finding has potentially important therapeutic implications as patients having positive anti-IFN antibodies could benefit from targeted interventions including plasmapheresis The aim of the current work is in a large cohort of patients with severe COVID-19 admitted in the ICU to determine the prevalence of patients with positive anti-IFN antibodies and to determine their outcome as compared to patients having negative anti-IFN antibodies
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None